retatrutide fda approval status clinical data 2026: Everything We Know So Far Retatrutide clinical trial done! Now – ⚠️ Before you consider using

While prior large-scale studies earlier in 2024 did not find an association between GLP-1 receptor agonists and retinopathy, this recent case series suggests that a subset of patients may be vulnerable to optic nerve damage and other vision complications [1,2]

None has yet entered Phase 3, and triple agonism remains the most-watched class in current clinical-trial publication

Eli Lilly is awaiting an FDA decision for a new indication for Mounjaro to reduce the risk of a major adverse cardiovascular event (MACE) in patients with type 2 diabetes mellitus (T2DM)

Regular monitoring of these markers helps detect potential liver stress from combining retatrutide with alcohol consumption before serious damage occurs

According to clinical trial data and post-marketing surveillance, these effects are generally dose-dependent (more common with higher doses) and tend to diminish over time as the body adapts to the medication

Liraglutide | Drugs | BNF | NICE